Cyclacillin

Summary

Cyclacillin (CHEMBL1200356) is an approved small-molecule antibacterial drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 341.4 Da · C15H23N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200356
Name	Cyclacillin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	19003
ChEBI	CHEBI:31444
Molecular formula	C15H23N3O4S
Molecular weight	341.4
InChIKey	HGBLNBBNRORJKI-WCABBAIRSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C

IUPAC name: (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Calthor, Ciclacilina, Ciclacillin, Ciclacilline, Cyclacillin, Cyclapen-w, NSC-88789, Vastcillin, Vasticillin, WY-4508, SID11112536, CYCLACILLIN

Patent coverage: 2,208 distinct patent families (8,320 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Fructose-bisphosphate aldolase, Prelamin-A/C, Solute carrier family 15 member 2, Muscarinic acetylcholine receptor M3, Solute carrier family 15 member 2, Cytochrome P450 3A4, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.9	Potency	1259	nM	CHEMBL_ACT_3637107
CHRM3	5.24	AC50	5700	nM	CHEMBL_ACT_25136287

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).